1. Armstrong D (1989) Problems in the treatment of opportunistic fungal infections. In: Holmberg K, Meyer RD (eds) Diagnosis and therapy of systemic fungal infections. Raven Press, New York, pp 149–158
2. Atkinson AJ, Bennett JE (1978) Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13: 271–276
3. Bennett JE (1977) Amphotericin B binding to serum ß-lipoprotein. In: Iwata K (ed) Recent advances in medical and veterinary mycology. Proc 6th ISHAM, University Park Press, Baltimore, USA, pp 107–109
4. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis.N Engl J Med 301: 126–131
5. Berger J, Duschinksy R (1962) Control of fungi with 5-fluorocytosine. US Pat Appl Ser No 181, p 822